Preclinical development of the novel Chk1 inhibitor SCH900776 in combination with DNA-damaging agents and antimetabolites

Molecular Cancer Therapeutics

Volumn 11, Issue 2, 2012, Pages 427-438

  Montano, Ryan ^a   Chung, Injae ^b   Garner, Kristen M ^a   Parry, David ^c   Eastman, Alan ^a  

^a NORRIS COTTON CANCER CENTER   (United States)

^b Duksung Women's University   (South Korea)

^c MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 MORPHOLINO 6 (1 THIANTHRENYL) 4 PYRANONE; 7 ETHYL 10 HYDROXYCAMPTOTHECIN; 7 HYDROXYSTAUROSPORINE; ANTINEOPLASTIC AGENT; CHECKPOINT KINASE 1; CISPLATIN; CYTARABINE; FLUOROURACIL; GEMCITABINE; HYDROXYUREA; SCH 900776; TIOGUANINE; UNCLASSIFIED DRUG;

ARTICLE; CELL CYCLE ARREST; CELL DEATH; CELL STRAIN HCT116; CONTROLLED STUDY; DNA REPLICATION; DOUBLE STRANDED DNA BREAK; ENZYME ACTIVATION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; SENSITIZATION;

ANTIMETABOLITES; ANTINEOPLASTIC AGENTS; BLOTTING, WESTERN; CAMPTOTHECIN; CELL CYCLE CHECKPOINTS; CELL LINE; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; CYTARABINE; DEOXYCYTIDINE; DNA BREAKS, DOUBLE-STRANDED; DNA DAMAGE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SCREENING ASSAYS, ANTITUMOR; DRUG SYNERGISM; FLOW CYTOMETRY; HUMANS; HYDROXYUREA; MOLECULAR STRUCTURE; PHOSPHORYLATION; PROTEIN KINASE INHIBITORS; PROTEIN KINASES; PYRAZOLES; PYRIMIDINES; STAUROSPORINE;

EID: 84856822207     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-11-0406     Document Type: Article

References (41)

1. Bucher N, Britten CD. G2 checkpoint abrogation and checkpoint kinase-1 targeting in the treatment of cancer. Br J Cancer 2008; 98:523-8. (Pubitemid 351214533)
2. Sausville EA, Arbuck SG, Messmann R, Headlee D, Bauer KS, Lush RM, et al. Phase I trial of 72-hour continuous infusion UCN- 01 in patients with refractory neoplasms. J Clin Oncol 2001;19: 2319-33. (Pubitemid 32366984)
3. Bunch RT, Eastman A. Enhancement of cisplatin-induced cytotoxicity by 7-hydroxystaurosporine (UCN-01), a new G2-checkpoint inhibitor. Clin Cancer Res 1996;2:791-7. (Pubitemid 26168931)
4. Kohn EA, Ruth ND, Brown MK, Livingstone M, Eastman A. Abrogation of the S phase DNA damage checkpoint results in S phase progression or premature mitosis depending on the concentration of UCN-01 and the kinetics of Cdc25C activation. J Biol Chem 2002;277:26553-64. (Pubitemid 34967153)
5. Wang Q, Fan S, Eastman A, Worland PJ, Sausville EA, O'Connor PM. UCN-01: a potent abrogator of G2 checkpoint function in cancer cells with disrupted p53. J Nat Cancer Inst 1996;88: 956-65. (Pubitemid 26239383)
6. Levesque AA, Kohn EA, Bresnick E, Eastman A. Distinct roles for p53 transactivation and repression in preventing UCN-01-mediated abrogation of DNA damage-induced S and G2 cell cycle checkpoints. Oncogene 2005;24:3786-96. (Pubitemid 40826877)
7. Fuse E, Tanii H, Kurata N, Kobayashi H, Shimada Y, Tamura T, et al. Unpredicted clinical pharmacology of UCN-01 caused by specific binding to human α1-acid glycoprotein. Cancer Res 1998;58:3248-53. (Pubitemid 28371060)
8. Perez RP, Lewis LD, Beelen AP, Olszanski AJ, Johnston N, Rhodes CH, et al. Modulation of cell cycle progression in human tumors: a pharmacokinetic and tumor molecular pharmacodynamic study of cisplatin plus the Chk1 inhibitor UCN-01 (NSC 638850). Clin Cancer Res 2006;12:7079-85. (Pubitemid 44974507)
9. Guzi T, Paruch K, Dwyer MP, Labroli M, Shanahan F, et al. Targeting the replication checkpoint using SCH900776, a potent and selective CHK1 inhibitor identified via high content functional screening. Mol Cancer Ther 2011;10:591-602.
10. Pommier Y. Topoisomerase I inhibitors: camptothecins and beyond. Nat Rev Cancer 2006;6:789-802. (Pubitemid 44450467)
11. Eastman A. Reevaluation of the interaction of cis-dichloro(ethylene- diamine) platinum(II) with DNA. Biochemistry 1986;25:3912-5. (Pubitemid 16042519)
12. 2 arrest and DNA double-strand breaks. Cancer Res 1988;48:4484-8.
13. Iwasaki H, Huang P, Keating MJ, Plunkett W. Differential incorporation of ara-C, gemcitabine and fludarabine into replicating and repairing DNA in proliferating human leukemia cells. Blood 1997;90: 270-8. (Pubitemid 27276571)
14. Zegerman P, Diffley JFX. DNA replication as a target of the DNA damage checkpoint. DNA Repair 2009;8:1077-88.
15. Cho SH, Toouli CD, Fujii GH, Crain C, Parry D. Chk1 is essential for tumor cell viability following activation of the replication checkpoint. Cell Cycle 2005;4:131-9. (Pubitemid 41038942)
16. Arienti KL, Brunmark A, Axe FU, McClure K, Lee A, Blevitt J, et al. Checkpoint kinase inhibitors: SAR and radioprotective properties of a series of 2-arylbenzimadoles. J Med Chem 2005;48:1873-85. (Pubitemid 40396318)
17. Zhang W-H, Poh A, Fanous AA, Eastman A. DNA damage-induced S phase arrest in human breast cancer depends on CHK1, but G2 arrest can occur independently of Chk1, Chk2 or MAPKAPK2. Cell Cycle 2008;7:1668-77. (Pubitemid 351881335)
18. Garner KM, Eastman A. Variations in Mre11/Rad50/Nbs1 status and DNA damage-induced S-phase arrest in cell lines of the NCI60 panel. BMC Cancer 2011;11:206.
19. Demarcq C, Bunch RT, Creswell D, Eastman A. The role of cell cycle progression in cisplatin-induced apoptosis in Chinese hamster ovary cells. Cell Growth Different 1994;5:983-93. (Pubitemid 24275113)
20. Rao J, Otto WR. Fluorometric DNA assay for cell growth estimation. Anal Biochem 1992;207:186-92.
21. 2 arrest. Mol Cancer Therap 2008;7:252-62.
22. Darzynkiewicz Z, Traganos F, Kapuscinski J, Staiano-Coico L, Melamed MR. Accessibility of DNA in situ to various fluorochromes: relationship to chromatin changes during erythroid differentiation of Friend leukemia cells. Cytometry 1984;5:355-63. (Pubitemid 14064787)
23. Clarke AAL, Clarke PR. DNA-dependent phosphorylation of Chk1 and claspin in a human cell-free system. Biochem J 2005;388:705-12. (Pubitemid 40839948)
24. Leung-Pineda V, Ryan CE, Piwnica-Worms H. Phosphorylation of Chk1 by ATRis antagonized by a Chk1-regulated protein phosphatase 2A circuit. Mol Cell Biol 2006;26:7529-38. (Pubitemid 44547703)
25. Zhao H, Watkins JL, Piwnica-Worms H. Disruption of the checkpoint kinase 1/cell division cycle 25A pathway abrogates ionizing radiationinduced S and G2 checkpoints. Proc Natl Acad Sci USA 2002; 99:14795-800. (Pubitemid 35334563)
26. Reinhardt HC, Aslanian AS, Lees JA, Yaffe MB. p53-Deficient cells rely on ATM- and ATR-mediated checkpoint signaling through the p38MAPK/MK2 pathway for survival after DNA damage. Cancer Cell 2007;11:175-89. (Pubitemid 46209849)
27. Eastman A, Kohn EA, Brown MK, Rathman J, Livingstone M, Blank DH, et al. Anovel indolocarbazole, ICP-1, abrogates DNA damage-induced cell cycle arrest and enhances cytotoxicity. Similarities and differences to the cell cycle checkpoint abrogator UCN-01. Mol Cancer Therap 2002;1:1067-78.
28. Bakkenist CJ, Kastan MB. DNA damage activates ATM through intermolecular autophosphorylation and dimer dissociation. Nature 2003;421:499-505.
29. Levesque AA, Eastman A. p53-based cancer therapies: is defective p53 the Achilles heel of the tumor? Carcinogenesis 2007;28:13-20. (Pubitemid 44942622)
30. Rodriguez-Bravo V, Guaita-Esteruelas S, Salvador N, Bachs O, Agell N. Different S/M checkpoint responses of tumor and non-tumor cell lines to DNA replication inhibition. Cancer Res 2007;67:11648-56.
31. Graves PR, Yu L, Schwarz JK, Gales J, Sausville EA, O'Connor PM, et al. The Chk1 protein kinase and the Cdc25C regulatory pathways are targets of the anticancer agent UCN-01. J Biol Chem 2000;275: 5600-5. (Pubitemid 30115197)
32. Busby EC, Leistritz DF, Abraham RT, Karnitz LM, Sarkaria JN. The radiosensitizing agent 7-hydroxystaurosporine (UCN-01) inhibits the DNA damage checkpoint kinase hChk1. Cancer Res 2000;60: 2108-12. (Pubitemid 30225168)
33. 2-M checkpoint independently of p53 by targeting both of the checkpoint kinases, Chk2 and Chk1. Cancer Res 2002;62:5743-8.
34. Feijoo C, Hall-Jackson C, Wu R, Jenkins D, Leitch J, Gilbert DM, et al. Activation ofmammalian Chk1 during DNA replication arrest: a role for Chk1 in the intra-S phase checkpoint monitoring replication origin firing. J Cell Biol 2001;154:913-23. (Pubitemid 34286172)
35. Petermann E, Orta ML, Issaeva N, Schultz N, Helleday T. Hydroxyurea-stalled replication forks become progressively inactivated and require two different RAD51-mediated pathways for restart and repair. Molecular Cell 2010;37:492-502.
36. Xiao Z, Xue J, Sowin TJ, Rosenberg SH, Zhang H. A novel mechanism of checkpoint abrogation conferred by Chk1 downregulation. Oncogene 2005;24:1403-11. (Pubitemid 40343120)
37. Robinson HM, Jones R, Walker M, Zachos G, Brown R, Cassidy J, et al. Chk1-dependent slowing of S-phase progression protects DT40 B-lymphoma cells against killing by the nucleoside analogue 5-fluorouracil. Oncogene 2006;25:5359-69. (Pubitemid 44330279)
38. Taricani L, Shanahan F, Parry D. Replication stress activates DNA polymerase alpha-associated Chk1. Cell Cycle 2009;8:482-9.
39. Shah N, Pang B, Yeoh K-G, Thorn S, Chen CS, Lilly MB, et al. Potential roles for the PIM1 kinase in human cancer-a molecular and therapeutic appraisal. Eur J Cancer 2008;44:2144-51.
40. Chen CC, Kennedy RD, Sidi S, Look AT, D'Andrea A. Chk1 inhibition as a strategy for targeting fanconi anemia (FA) DNA repair pathway deficient tumors. Mol Cancer 2009;8:24.
41. Belt RJ, Haas CD, Kennedy J, Taylor S. Studies of hydroxyurea administed by continous infusion: toxicity, pharmacokinetics, and cell synchronization. Cancer 1980;46:455-62. (Pubitemid 10036635)